Skip to main content
. Author manuscript; available in PMC: 2011 Dec 7.
Published in final edited form as: Circulation. 2010 Dec 7;122(23):2430–2440. doi: 10.1161/CIRCULATIONAHA.110.978924

Figure 4. Clinical outcomes are worse for HCM patients with sarcomere mutations (myofilament-positive), compared to those without mutations (myofilament-negative).20.

Figure 4

A. Myofilament-positive patients have a higher probability of cardiovascular (CV) death, nonfatal ischemic stroke, or progression to severe heart failure symptoms (New York Health Association (NYHA) functional classes III or IV).

B. Myofilament-positive patients have a higher probability of developing systolic dysfunction, defined as LV ejection fraction <50%.

C. Myofilament-positive patients have a higher probability of developing restrictive LV filling pattern, defined as transmitral early deceleration time <120 ms or a ratio of peak mitral early to late diastolic filling velocity (E/A ratio) of ≥ 2 in conjunction with a deceleration time of ≥ 150 ms.

Adapted with permission from Olivotto I. et al. Mayo Clinic proceedings 2008;83(6):630–8.